Pharsight

Sincalide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11318100 MAIA PHARMS INC Storage stable sincalide formulations
Apr, 2038

(14 years from now)

US11110063 MAIA PHARMS INC Storage stable sincalide formulations
Apr, 2038

(14 years from now)

US11737983 MAIA PHARMS INC Storage stable sincalide formulations
Apr, 2038

(14 years from now)

Sincalide is owned by Maia Pharms Inc.

Sincalide contains Sincalide.

Sincalide has a total of 3 drug patents out of which 0 drug patents have expired.

Sincalide was authorised for market use on 22 November, 2022.

Sincalide is available in powder;intravenous dosage forms.

Sincalide can be used as diagnosis of gall bladder disorders or other diagnostic imaging by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; diagnosis of pancreatic disorders by stimulating pancreatic secretion in combination with secretin prior to obtajning a duodenal aspirate for analysis; diagnostic imaging by accelerating the tran it ofa barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract, diagnosis of pancreatic disorders by stimulating pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis; diagnosis of gall bladder disorders by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis, accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract; stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis; stimulate gallbladder contraction. as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis.

The generics of Sincalide are possible to be released after 20 April, 2038.

Drugs and Companies using SINCALIDE ingredient

Market Authorisation Date: 22 November, 2022

Treatment: Accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract; Stimulat...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

SINCALIDE family patents

Family Patents